Pharma Business - May 9, 2022
Aqilion strengthens its pipeline
Aqilion has nominated Girtab, a program from the company’s research activities, for further preclinical and clinical development. The goal of Girtab is to develop a new treatment for chronic inflammatory bowel diseases (IBD). Girtab complements Aqilion’s pipeline well and strengthens the company’s strategic focus on drug targets and programs with great potential in inflammatory diseases, […]
In a new job - January 20, 2022
Aqilion appoints new Head of Preclinical Development
Anneli Hällgren has been appointed the new head of preclinical development, including regulatory safety studies. Hällgren has worked for the past ten years as a consultant in preclinical drug discovery and will now join the Aqilion team on a part-time basis. “I’m convinced that Anneli Hällgren’s expertise will be extremely valuable for Aqilion’s continued preparations […]
Acquisition - December 6, 2021
Aqilion acquires anti-inflammatory program from LEO Pharma
Aqilion has strengthened its pipeline with an innovative development program in the field of chronic inflammation. With this acquisition, Aqilion is taking over all rights to the program, now under the name Regulus, from LEO Pharma. The project is ready for clinical trials and Aqilion plans to begin clinical development in 2022. Aqilion will make an […]
In a new job - March 5, 2021
He is the new Chief Scientific Officer at Aqilion
Johan Lund, the current Chairman of the company, will join the operational team as Chief Scientific Officer. Johan Lund will mainly contribute his expertise in the field of inflammation research, which is Aqilion’s research priority. “Inflammation is a field in which new biological research findings make it possible to address serious diseases in new ways. […]
Financing - August 2, 2019
Aqilion receives SEK 100 million through conversion of outstanding warrants
In March of 2018, Aqilion AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of units. Each unit consisted of one share and two warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which raised an […]
